PROG | Future timeline and revenue

Updated: Jan 2

Optifinancial Newsletter - Knowledge is power - Brad Mitchell

This is not financial advice nor recommendations. This is purely our own thoughts and opinions regarding the matter discussed below for entertainment purposes. This is not advice and is never intended to be.

Disclosure: We own PROG securities/shares at the time of publication. This could affect my biases in my analysis.


Progenity | $2.10

  • First Edition Analysis showing Company Pathway to 2032

  • Continual update and refresh of analysis will be performed to as company continues

  • Shared below


Click the button below to go to the spreadsheet with estimations of market uptake and when the product lines such as the DDS and the OBDS go to market. To date, I have not included the the PIL DX and the RSS product lines but will add those in the future.

(Added screenshots below for ease of access)

Here's a 10 year log-scaled chart of the share price prediction from 2022-2032:

Progenity's share price shown in the graph above, based off of revenue predictions, and commercialization timeline.

After deep diving against Progenity's technology versus their competitors, I believe that they could well be on their way to dominating the oral delivery market.

This is my first edition analysis and expect to refine it with tighter and more accurate information in the future. I hope this gives you insight on what Progenity could do in the future.

Final thought on PROG: After a 2021 filled with uncertainty, doubt and extremely high scrutiny of Progenity, I see this company turning around in a strong fashion as they have a fresh management, acquired funds to make it to 2023 and have some final pieces to the puzzle being answered before mid 2022 (PkPd enema study for adalimumab)

Disclosure: We own PROG securities/shares at the time of publication

All stocks talked about we have invested in, and do not intend to give advice nor recommend acting upon the information.


Thanks for subscribing to the newsletter. If you find this information helps you, please share it with someone else! It will help us out greatly.

Until next week,

Brad Mitchell

and the Optifinancial Team



Optifinancial is not a certified financial planner/advisor nor a certified financial analyst nor an economist nor a CPA ;nor an accountant nor a lawyer. Optifinancial is not a finance professional through formal education. Optifinancial believes in and takes pride in a sense of freedom, satisfaction, fulfillment and empowerment of money. The contents on this site/letter/email are for informational and entertainment purposes only and does not constitute financial, accounting, or legal advice. Optifinancial can’t promise that the information shared on our posts is appropriate for you or anyone else. By using our content, you agree to hold Optfinancial or any constituents related to Optifinancial harmless from any ramifications, financial or otherwise, that occur to you as a result of acting on information provided through our site, website, social media and newsletter.


Optifinancial does not collect information about you other than (1) what you personally provide if you submit a comment (your email will not be published) or sign up for our newsletter updates and (2) what’s available through normal server logs and Google Analytics. Optifinancial won’t sell or disclose your information to others unless we have received prior written agreement from you (e.g., you agreed to let me share your comment on a post with other readers).

17350 State Highway 249

Ste 220 #3942

Houston, Texas 77064

1,838 views0 comments

Recent Posts

See All